Metatron Health

Botanical species · safety record

Anemarrhena asphodeloides

The EFSA Compendium of Botanicals holds 1 constituent measurement and 1 adverse-effect record for Anemarrhena asphodeloides. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Anemarrhena asphodeloides Bunge

1Constituent measurements
1Safety records
2Cited sources
499Licensed products (Canada)

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 499 licensed products naming Anemarrhena asphodeloides as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Extract types on licence

  • Dry
  • Extract Type TBA
  • decoction
  • solid

Source material stated

  • Anemarrhena asphodeloides
  • Dried rhizome
  • Rhizoma
  • Rhizome
  • Rhizome (Fried in salt)
  • Rhizome (Stir-baked with salt)
  • Rhizome(s)
  • Root

What the records describe

Constituents measured

  • Saponins1

Plant parts

  • Roots and other underground parts1
  • Unspecified1

Preparations

  • Solvent extraction1

Effect types

  • Hepatotoxicity1

Target tissues

  • Liver1

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

SubstancePlant partPreparationConcentrationAnalytical methodSource
SaponinsRoots and other underground partsSolvent extraction—HPLC with standard detection methodsResolve DOI

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

EffectTarget tissuePlant partPreparationTest organismTest typeSource
HepatotoxicityLiverUnspecified—Rat (as animal)Short-term toxicityResolve DOI

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

  1. Wu, Zhi-tao., Qi, Xin-ming., Sheng, Jing-jing., Ma, Lei-lei., Ni, Xuan., Ren, Jin., Huang, Cheng-gang., Pan, Guo-yu. Timosaponin A3 induces hepatotoxicity in rats through inducing oxidative stress and down-regulating bile acid transporters. ACTA PHARMACOLOGICA SINICA, 2014, vol. 35, no. 9, p. 1188-1198. DOI
  2. Wu, Xiaoyi., Chao, Zhimao., Wang, Chun., Yu, Li. Separation of chemical constituents from three plant medicines by counter-current chromatography using a three-phase solvent system at a novel ratio. JOURNAL OF CHROMATOGRAPHY A, 2015, vol. 1384, p. 107-114. DOI

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature

Europe PMC

Every record indexed for this species, resolvable and re-runnable.

All species

Substance index

Search and browse every species this world holds under source and hash.

Before anything else

Safety Centre

Interactions, contraindications and the escalation boundary this world does not cross.

In its own terms

Traditions

How the living traditions approach preparation, use and context.